A carregar...
CAR T‐Cell Therapy Shows Durable Responses in Indolent NHL
In an update from the ongoing phase II ZUMA‐5 trial, axicabtagene ciloleucel showed a high response rate and durable clinical benefit in patients with relapsed/refractory indolent non‐Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330923/ https://ncbi.nlm.nih.gov/pubmed/32588925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0559 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|